| Chronic Obstructive Airway Disease

Dalisrep vs Trelegy Ellipta

Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.

Deep comparison between: Daliresp vs Trelegy Ellipta with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTrelegy Ellipta has a higher rate of injection site reactions vs Daliresp based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Trelegy Ellipta but not Daliresp, including UnitedHealthcare

Category

Daliresp

Trelegy Ellipta

At A Glance

RouteOral

FrequencyDaily

ClassPDE4 inhibitor

RouteOral inhalation

FrequencyOnce daily

ClassICS/LAMA/LABA

Indications

Chronic Obstructive Airway Disease

Chronic Obstructive Airway Disease
Asthma

Dosing

Chronic Obstructive Airway Disease Maintenance dose: 500 mcg once daily, with or without food; an optional titration of 250 mcg once daily for the first 4 weeks may reduce discontinuation rates, but 250 mcg is not the effective therapeutic dose.

Chronic Obstructive Airway Disease 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.

Asthma 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg or 200/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.

Contraindications

Moderate to severe liver impairment (Child-Pugh B or C)

Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any excipient

Drug Interactions

977View drug interactions

2406View drug interactions

Adverse Reactions

Most common (>=2%) Diarrhea, weight decreased, nausea, headache, back pain, influenza, insomnia, dizziness, decreased appetite

Serious Diarrhea, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, acute renal failure

Postmarketing Hypersensitivity reactions (angioedema, urticaria, rash), gynecomastia

Most common (>=1%) Headache, back pain, nasopharyngitis, upper respiratory tract infection, bronchitis, dysgeusia, cough, oropharyngeal pain, diarrhea, influenza, sinusitis, oral candidiasis, arthralgia, dysphonia, pneumonia, urinary tract infection, rhinitis, constipation, gastroenteritis

Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma, worsening of urinary retention

Postmarketing Palpitations, blurred vision, eye pain, glaucoma, intraocular pressure increase, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, anxiety, dysuria, urinary retention

Pharmacology

Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4); inhibition of PDE4 leads to accumulation of intracellular cyclic AMP in lung tissue, which is thought to underlie its therapeutic action in COPD.

TRELEGY ELLIPTA combines fluticasone furoate (ICS), umeclidinium (long-acting muscarinic antagonist), and vilanterol (LABA); fluticasone furoate reduces airway inflammation via glucocorticoid receptor activation, umeclidinium produces bronchodilation through M3 muscarinic receptor inhibition, and vilanterol relaxes bronchial smooth muscle through beta2-adrenergic receptor stimulation and increased cyclic AMP.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Daliresp